Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of MC4 Agonist in Patients With Male Erectile Dysfunction

Status: Completed

Protocol number: NU18390

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A randomized, double-blind study of the safety and efficacy of MC4 Agonist, compared to that of sildenafil, in patients with male erectile dysfunction

Brief summary: This study will evaluate the efficacy, safety, and tolerability of MC4 Agonist, compared to placebo and sildenafil, in patients with male erectile dysfunction (MED). The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals. Target sample size is 48.

Study phase: II

Study type: Interventional; Treatment; Randomized; Double Blind; Active; Parallel; Safety/Efficacy study

Condition: Erectile Dysfunction

Intervention type: Drug

Intervention name: MC4 Agonist

Primary outcome: 1. Safety: Vital signs, ECGs, clinical laboratory tests, observed and self-reported adverse events Efficacy: Cumulative duration of rigidity greater than or equal to 60% at the base of the penis from 15 minutes postdose through 140 minutes postdose

Key secondary outcomes: 1. Efficacy: Cumulative duration of rigidity greater than or equal to 80% at the base of the penis, cumulative duration of rigidity greater than or equal to 60% and 80% at the tip of the penis

Inclusion criteria:

  • male patients 21-65 years of age;
  • MED of a continual duration of >=6 months;
  • mild to moderate MED documented at screening.

Exclusion criteria:

  • participation in an investigational drug or medical device study within the last 30 days;
  • if capable of reproduction, unwillingness to use an effective form of contraception;
  • conditions that predispose to priapism.

Gender: Males

Age limits: Min: 21 Years Max: 65 Years

Accepts healthy volunteers: No

Trial registration date: 08/17/2005

Date last updated: 11/21/2008


Link to trial result

This trial was conducted at the following locations:

United States

  • Huntsville, AL
  • Tarzana, CA
  • Waterbury, CT
  • Piscataway, NJ

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply